GSK Press Releases - EIN Presswire - Press Release Distribution Service

Published on June 1, 2014 - 12:43 GMT

GSK announces Phase III ALTTO results for anti-HER2 therapy combination in the adjuvant breast cancer treatment setting

Issued: 1 June 2014, London UK GlaxoSmithKline plc (LSE: GSK) today announced that the Phase III study of two anti-HER2 agents, lapatinib (Tykerb™/Tyverb™) and trastuzumab, did not meet the primary endpoint of improved disease free survival (DFS) compared …

Distribution channels: Companies

Published on May 27, 2014 - 19:44 GMT

Serious Fraud Office Investigation

Issued: 27 May 2014, London UK – LSE announcement GlaxoSmithKline plc (LSE/NYSE: GSK) has today been informed by the UK’s Serious Fraud Office (SFO) that it has opened a formal criminal investigation into the Group’s commercial practices. GSK is committed …

Distribution channels: Companies

Published on May 23, 2014 - 15:44 GMT

GSK and Genmab receive CHMP positive opinion for Arzerra (ofatumumab) in combination with chlorambucil or bendamustine as a first-...

Issued: Friday 23 May 2014, London UK GlaxoSmithKline plc (LSE: GSK) and Genmab A/S (OMX: GEN) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending …

Distribution channels: Companies

Published on May 23, 2014 - 09:34 GMT

GSK announces regulatory submission for umeclidinium monotherapy for COPD in Japan

GlaxoSmithKline plc (LSE: GSK) today announced the submission of a regulatory application to the Japanese Ministry of Health, Labour and Welfare (MHLW) for umeclidinium (UMEC), a long-acting muscarinic antagonist (LAMA), administered using the Ellipta™ dry …

Distribution channels: Companies

Published on May 20, 2014 - 11:48 GMT

GSK announces new commitment to improve access to vaccines with 5-year price freeze for countries graduating from GAVI Alliance ...

GSK announced today that it will freeze the prices of its vaccines for five years for developing countries that graduate from GAVI Alliance support. By committing to offer GAVI Alliance prices for vaccines against pneumococcal disease, rotavirus and …

Distribution channels: Companies

Published on May 19, 2014 - 21:26 GMT

GSK presents positive data at ATS 2014 from study evaluating efficacy and safety of Incruse™ Ellipta® added to Advair® Diskus® in ...

Issued: Monday 19 May 2014, London UK GlaxoSmithKline plc (LSE:GSK) today presented data at the American Thoracic Society (ATS) from a late-stage clinical study. In this study the safety and efficacy of the addition of a long-acting muscarinic antagonist ( …

Distribution channels: Companies

Published on May 19, 2014 - 19:20 GMT

GSK and Genmab announce top-line results from a pivotal head-to-head study of ofatumumab in combination with chemotherapy vs. ...

Issued: 19 May 2014, London UK GlaxoSmithKline plc (LSE: GSK) and Genmab A/S (OMX: GEN) announced today that the Phase III study (ORCHARRD) of ofatumumab (Arzerra™) plus chemotherapy versus rituximab plus chemotherapy to treat relapsed or refractory …

Distribution channels: Companies

Published on May 13, 2014 - 07:08 GMT

GSK announces phase III study with darapladib did not meet primary endpoint in patients following an acute coronary syndrome

GlaxoSmithKline (LSE/NYSE: GSK) today announced headline results from its second phase III study with darapladib, SOLID-TIMI 52, evaluating the efficacy of its investigational Lp-PLA2 inhibitor in adults following an acute coronary syndrome. In the study, …

Distribution channels: Companies

Published on May 8, 2014 - 15:49 GMT

Anoro® (umeclidinium/vilanterol) gains marketing authorisation in Europe for the treatment of COPD

GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the European Commission has granted marketing authorisation for Anoro® (umeclidinium/vilanterol) as a once-daily, maintenance bronchodilator treatment to relieve …

Distribution channels: Companies

Published on April 30, 2014 - 23:03 GMT

GSK receives approval for Incruse™ Ellipta® (umeclidinium) in the US for the treatment of COPD

Issued: Wednesday 30 April 2014, London UK – LSE announcement GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Incruse™ Ellipta® (umeclidinium) as an anticholinergic indicated for the long-term …

Distribution channels: Companies

Published on April 30, 2014 - 13:51 GMT

Results announcement for the first quarter 2014

An overview of what GSK does worldwide including information on our three main business areas: Pharmaceuticals, Vaccines and Consumer HealthcareDo you have a question about GSK group or one of our products? We are a large global organisation, so please …

Distribution channels: Companies

Published on April 29, 2014 - 15:13 GMT

GSK announces start of phase III programme for mepolizumab in patients with COPD

GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the start of a phase III programme to evaluate the efficacy and safety of mepolizumab as an adjunctive therapy for adults who have severe chronic obstructive pulmonary disease (COPD). The programme will …

Distribution channels: Companies

Published on April 28, 2014 - 16:16 GMT

GSK receives EU marketing authorisation for Incruse (umeclidinium) for the treatment of COPD

Issued: Monday 28 April 2014, London UK – LSE Announcement GlaxoSmithKline plc (LSE/NYSE: GSK) announced today that the European Commission has granted marketing authorisation for Incruse® (umeclidinium) as a once-daily, maintenance bronchodilator …

Distribution channels: Companies

Published on April 28, 2014 - 11:53 GMT

GSK and MMV announce start of phase III programme of tafenoquine for Plasmodium vivax malaria

Issued: Monday 28 April 2014, London UK GlaxoSmithKline (GSK) and Medicines for Malaria Venture (MMV) today announced the start of a phase III global programme to evaluate the efficacy and safety of tafenoquine, an investigational medicine which is being …

Distribution channels: Companies

Published on April 25, 2014 - 14:54 GMT

GSK receives positive CHMP opinion for Mekinist™ (trametinib) in metastatic melanoma with a BRAF V600 mutation

GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending marketing authorisation for Mekinist™(trametinib) as a …

Distribution channels: Companies

Published on April 22, 2014 - 13:03 GMT

GSK and Theravance announce phase III study of fluticasone furoate/vilanterol in COPD commenced to support potential future filing ...

GlaxoSmithKline (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX)today announced the start of a Phase III efficacy and safety study of a combination treatment of the inhaled corticosteroid (ICS), fluticasone furoate and long-acting beta2 agonist (LABA), …

Distribution channels: Companies

Published on April 22, 2014 - 05:47 GMT

GSK plc announces major three-part transaction with Novartis to drive sustainable sales growth, improve long-term earnings and ...

Issued Tuesday 22 April 2014, London UK - LSE announcement GlaxoSmithKline plc today announces a major 3-part inter-conditional transaction with Novartis AG involving its Consumer Healthcare, Vaccines and Oncology businesses (the “Transaction”). In summary …

Distribution channels: Companies

Published on April 17, 2014 - 23:38 GMT

GSK and Genmab receive FDA approval for Arzerra® (ofatumumab) as first-line treatment in combination with chlorambucil for ...

Issued: 17 April 2014, London UK GlaxoSmithKline plc (LSE: GSK) and Genmab A/S (OMX: GEN) announced today that the U.S. Food and Drug Administration (FDA) has approved a Supplemental Biologic License Application (sBLA) for the use of Arzerra® (ofatumumab), …

Distribution channels: Companies

Published on April 17, 2014 - 15:59 GMT

GSK announces approval in Canada for Incruse Ellipta (umeclidinium) as a treatment for COPD

Issued: Thursday 17 April 2014, London UK – LSE Announcement GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that Incruse™ Ellipta™ (umeclidinium, as umeclidinium bromide) has received market authorisation in Canada for the long-term once-daily …

Distribution channels: Companies

Published on April 16, 2014 - 18:43 GMT

GSK statement on media reports

Issued Tuesday 16 April 2014 There has been recent publicity on cases of alleged misconduct by GSK employees in a number of countries. This is a result of details of these cases being made available to the media. In response to coverage today on GSK …

Distribution channels: Companies